Literature DB >> 17962814

Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin.

J A Bernal1, M Roche, C Méndez-Vidal, A Espina, M Tortolero, J A Pintor-Toro.   

Abstract

The faithful repair of DNA damage, especially chromosomal double-strand breaks (DSBs), is crucial for genomic integrity. We have previously shown that securin interacts with the Ku70/80 heterodimer of the DSB non-homologous DNA end-joining (NHEJ) repair machinery. Here we demonstrate that securin deficiency compromises cell survival and proliferation, but only after genotoxic stress. Securin(-/-) cells show a significant increase in gross chromosomal rearrangements and chromatid breaks after DNA damage, and also reveal an altered pattern of end resection in an NHEJ assay in comparison with securin(+/+) cells. These data suggest that securin has a key role in the maintenance of genomic stability after DNA damage, thereby providing a previously unknown mechanism for regulating tumour progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962814     DOI: 10.1038/sj.cdd.4402254

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  22 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Authors:  Mar Mora-Santos; M Cristina Limón-Mortés; Servando Giráldez; Joaquín Herrero-Ruiz; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

3.  Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.

Authors:  Ning-Ai Liu; Hong Jiang; Anat Ben-Shlomo; Kolja Wawrowsky; Xue-Mo Fan; Shuo Lin; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

4.  p21(Cip1) restrains pituitary tumor growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kalman Kovacs; Anat Ben-Shlomo; Kolja Wawrowsky; Serguei Bannykh; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

5.  E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

Authors:  Cuiqi Zhou; Kolja Wawrowsky; Serguei Bannykh; Shiri Gutman; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-10-16

6.  Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence.

Authors:  Vera Chesnokova; Chris Wong; Svetlana Zonis; Anna Gruszka; Kolja Wawrowsky; Song-Guang Ren; Anat Benshlomo; Run Yu
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

Review 7.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

8.  PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.

Authors:  Michael J Demeure; Kathryn E Coan; Clive S Grant; Richard A Komorowski; Elizabeth Stephan; Shripad Sinari; David Mount; Kimberly J Bussey
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

9.  Does securin expression have significance in prognostication of oral tongue cancer? A pilot study.

Authors:  Ilkka Heikkinen; Alhadi Almangush; Jaana Hagström; Ibrahim O Bello; Joonas H Kauppila; Laura K Mäkinen; Caj Haglund; Pentti Nieminen; Tuula Salo; Ilmo Leivo
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-18       Impact factor: 2.503

10.  Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation.

Authors:  Agueda G Espina; Cristina Méndez-Vidal; Miguel A Moreno-Mateos; Carmen Sáez; Ana Romero-Franco; Miguel A Japón; José A Pintor-Toro
Journal:  Mol Biol Cell       Date:  2009-05-28       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.